Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My question to you Mr. Kempers is WHO IS THE Ecology partner in the Netherlands? you have not disclosed that. Do you have any thing on the up and up Mr. Kempers? HIV MR. KEMPERS?
PCI Biotech: US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants
March 26, 2020 04:12 ET | Source: PCI Biotech Holding ASA
https://www.globenewswire.com/news-release/2020/03/26/2006763/0/en/PCI-Biotech-US-patent-for-the-vaccine-technology-fimaVacc-with-a-new-important-class-of-adjuvants.html
The fimaVacc programme aims to enhance the cellular immune responses that are important for the therapeutic effect of vaccines, and the fimaVacc technology has proven excellent preclinical efficacy with protein- and peptide-based vaccines. The technology has shown particularly strong CD8 T-cell immune responses, which are important for therapeutic vaccination, as well as enhanced helper (CD4) T-cell and antibody responses.
https://www.mjzanon.com/brazilian-ip-news/pci-biotech-us-patent-granted-for-the-vaccine-technology-fimavacc-in-combination-with-cytokines/
Virosomes as a carrier delivery system for mRNA or adeno virus vector based vaccine candidates
University College London Department of Biochemical Engineering
Project Context and Objectives:
The aim of this project will be to evaluate the feasibility of incorporating candidate mRNA sequences of various sizes into virosomes through different methods including encapsulation, surface linkage and with linkers. The potency and long-term stability of these virosomes will then be evaluated and also formulated for enhanced stability.
Knowledge gained from this project could offer valuable tools that may also be applied to other virosome-based therapies, such as gene therapies.
https://www.findaphd.com/phds/project/virosomes-as-a-carrier-delivery-system-for-mrna-or-adeno-virus-vector-based-vaccine-candidates/?p132145
New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
Promising vaccine technology has generated strong immune responses in mice and primates
Date:
August 10, 2022
Source:
University of Minnesota
Summary:
Researchers have developed a new way to effectively deliver vaccines through the nose that could lead to better protection against diseases like HIV and COVID-19.
A University of Minnesota assistant professor is part of a team that has developed a new way to effectively deliver vaccines through mucosal tissues in the nose that could lead to better protection against pathogens like human immunodeficiency virus (HIV) and SARS-CoV-2, the virus that causes COVID-19.
Hartwell is continuing to study and develop this new vaccine technology in her lab at the University of Minnesota Twin Cities and hopes to adapt it to other diseases and illnesses in the future.
The research was funded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases; the National Cancer Institute; the Marble Center for Cancer Nanomedicine; the U. S. Army Research Office through the Institute for Soldier Nanotechnologies at the Massachusetts Institute of Technology; the Ragon Institute of MIT, Massachusetts General Hospital, and Harvard University; and the Bill and Melinda Gates Foundation.
In addition to Hartwell, the research team included Massachusetts Institute of Technology researchers Mariane Melo, Ashley Lemnios, Na Li, Jason Chang, Laura Maiorino, Tyson Moyer, Neil Dalvie, Sergio Rodriguez-Aponte, Kristen Rodrigues, Murillo Silva, Heikyung Suh, Josetta Adams, J. Christopher Love, and Professor Darrell Irvine; New Iberia Research Center and University of Louisiana at Lafayette researchers Peng Xiao, Crystal Carter, Jane Fontenot, Francois Villinger, and Ruth Ruprecht; Harvard Medical School researchers Jingyou Yu, Makda Gebre, Aiquan Chang, and Dan Barouch.
https://www.sciencedaily.com/releases/2022/08/220810105212.htm
Study investigates the production of a virosome-based COVID-19 vaccine candidate
https://www.news-medical.net/news/20220418/Study-investigates-the-production-of-a-virosome-based-COVID-19-vaccine-candidate.aspx
Christiane Kempers-Francke’s Post
https://www.linkedin.com/posts/chkempers_fresenius-kabi-announces-acceptance-of-its-activity-6966052178465587202-Lxv-
Toon Stegmann
Scientific Advisory Board
Forbes and Dunagan
Romania
https://biography.omicsonline.org/romania/forbes-and-dunagan/toon-stegmann-1231465
DESCRIPTION
Recombinant Major pollen allergen Bet v 1-A produced in SF9 is a glycosylated, polypeptide chain having a calculated molecular mass of 18,942 Dalton.
Bet v 1.0101 is expressed with a 10xHis tag at N-terminus and purified by proprietary chromatographic techniques.
SOURCE
Sf9 insect cells.
Major pollen allergen Bet v 1-A Recombinant, Sf9
https://www.prospecbio.com/bet_v_10101
Study investigates the production of a virosome-based COVID-19 vaccine candidate
For all N-linked glycan sites already identified in current literature, purified S protein was analyzed using liquid chromatography-mass spectrometry (LC-MS) to determine site-specific glycosylation and glycan composition. At glycosylation sites N 68_81, N172, N241, and N1081, a combination of high mannose and complex/paucimannose-type glycans were discovered; the remaining 15 sites were dominated by processed, complex-type glycans.
https://www.news-medical.net/news/20220418/Study-investigates-the-production-of-a-virosome-based-COVID-19-vaccine-candidate.aspx
DESCRIPTION
Recombinant Major pollen allergen Bet v 1-A produced in SF9 is a glycosylated, polypeptide chain having a calculated molecular mass of 18,942 Dalton.
Bet v 1.0101 is expressed with a 10xHis tag at N-terminus and purified by proprietary chromatographic techniques.
SOURCE
Sf9 insect cells.
Major pollen allergen Bet v 1-A Recombinant, Sf9
https://www.prospecbio.com/bet_v_10101
Jane Fontenot https://orcid.org/0000-0002-1846-7915
New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Jane Fontenot
Director of Contract Research
UL Lafayette
New Iberia, Louisiana, United States
ExperienceExperience
Head, Research ResourcesHead, Research Resources
UL LafayetteUL Lafayette
1998 - Present · 24 yrs 8 mos1998 - Present · 24 yrs 8 mos
New Iberia LA 70560
HEY MR. KEMPERS, DOES BELTRAMI CONSULITING STILL HAVE THIS?
WHY HAS THIS NOT BEEN BOUGHT OUT BY BIG PHARMA?
COME ON BILLIONAIRES SELL THIS TO BIG PHARMA!!!!!!!!!!!!!!!
Results: Both types of adjuvanted virosomes coupled to Bet v 1 COPs triggered a boosted Th1 immunity. Given a more favourable safety profile, Vir.A-Bet v 1 COPs were further evaluated and shown to able to fully reverse asthma symptoms and lung inflammation in a sublingual therapeutic model of birch pollen allergy.
https://pubmed.ncbi.nlm.nih.gov/33368719/
Maria Elena Bottazzi
https://orcid.org/orcid-search/search?searchQuery=virosomes
Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant
by Laura Fernández 1,†,Jose Carlos Solana 1,*,†ORCID,Carmen Sánchez 1,Mª Ángeles Jiménez 2,Jose M. Requena 3ORCID,Rhea Coler 4,Steven G. Reed 5,Jesus G. Valenzuela 6,Shaden Kamhawi 6,Fabiano Oliveira 6,Epifanio Fichera 7,Reinhard Glueck 7,‡,Maria Elena Bottazzi 8ORCID,Gaurav Gupta 7,Pedro Cecilio 9,10,11ORCID,Begoña Pérez-Cabezas 9,10,Anabela Cordeiro-da-Silva 9,10,11ORCID,Luigi Gradoni 12ORCID,Eugenia Carrillo 1,§ORCID andJavier Moreno 1,§ORCID
https://www.mdpi.com/2076-2607/9/11/2253
https://doaj.org/article/117c18657fb5436286218190c48f7d64
Continue from last post
CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT
Award Number: UM1AI144462
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
Issue Date FY
Sort Order Descending
Funding FY
Sort Order Descending
Legal Entity Name
Legal Entity Address
Legal Entity City
Legal Entity State
Legal Entity Zip Code
Legal Entity COUNTY
Legal Entity COUNTRY
Assistance Listing
Award Code
Budget Year
Action Date
Action Type
Action Amount
Collapse Issue Date FY: 2022 ( Subtotal = $21,000,000 )
2022 2022 SCRIPPS RESEARCH INSTITUTE, THE 10550 NORTH TORREY PINES RD LA JOLLA CA 92037 SAN DIEGO USA Allergy and Infectious Diseases Research 001 4 7/13/2022 NON-COMPETING CONTINUATION $21,000,000
https://taggs.hhs.gov/Detail/AwardDetail?arg_AwardNum=UM1AI144462&arg_ProgOfficeCode=104
Winning by a nose
Despite the fact that many viruses initially enter the body through mucosal surfaces, most vaccines are administered by nonmucosal routes. This is, in part, due to historically poor development of immune responses after mucosal immunization. To address this, Hartwell et al. developed lipid-conjugated immunogens, called amph-proteins, and administered them intranasally to mice and nonhuman primates; these vaccines, which used the neonatal Fc receptor to mediate transmucosal uptake, elicited immune responses at both local and distal mucosal sites. These data support further development of amph-protein–based intranasal vaccines for immunogens such as the SARS-CoV-2 receptor binding domain and the HIV envelope protein, among others.
Intranasal immunization with amph-conjugated HIV Env gp120 or SARS-CoV-2 receptor binding domain (RBD) proteins elicited 100- to 1000-fold higher antigen-specific IgG and IgA titers in the serum, upper and lower respiratory mucosa, and distal genitourinary mucosae of mice compared to unmodified protein. Amph-RBD immunization induced high titers of SARS-CoV-2–neutralizing antibodies in serum, nasal washes, and bronchoalveolar lavage. Furthermore, intranasal amph-protein immunization in rhesus macaques elicited 10-fold higher antigen-specific IgG and IgA responses in the serum and nasal mucosa compared to unmodified protein, supporting the translational potential of this approach. These results suggest that using amph-protein vaccines to deliver antigen across mucosal epithelia is a promising strategy to promote mucosal immunity against HIV, SARS-CoV-2, and other infectious diseases.
AffiliationsExpand All
Brittany L. Hartwell https://orcid.org/0000-0002-5438-9010
Mariane B. Melo https://orcid.org/0000-0002-0409-2454
Peng Xiao https://orcid.org/0000-0002-5308-8400
Ashley A. Lemnios
Na Li
Jason Y.H. Chang https://orcid.org/0000-0002-2238-8232
Jingyou Yu https://orcid.org/0000-0002-0775-6623
Makda S. Gebre https://orcid.org/0000-0001-8520-2178
Aiquan Chang https://orcid.org/0000-0002-9482-0979
Laura Maiorino https://orcid.org/0000-0001-8217-1337
Crystal Carter https://orcid.org/0000-0001-8929-3839
Tyson J. Moyer
Neil C. Dalvie https://orcid.org/0000-0002-7912-0309
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Roles: Investigation, Resources, and Writing - review & editing.
View all articles by this author
Sergio A. Rodriguez-Aponte https://orcid.org/0000-0002-6271-7918
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Role: Resources.
View all articles by this author
Kristen A. Rodrigues https://orcid.org/0000-0002-0680-9834
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.
Harvard-MIT Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Roles: Formal analysis, Investigation, Methodology, Resources, and Writing - review & editing.
View all articles by this author
Murillo Silva https://orcid.org/0000-0003-4668-6290
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.
Roles: Investigation and Resources.
View all articles by this author
Heikyung Suh
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Roles: Methodology, Project administration, and Resources.
View all articles by this author
Josetta Adams https://orcid.org/0000-0001-6416-2330
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Roles: Formal analysis and Investigation.
View all articles by this author
Jane Fontenot https://orcid.org/0000-0002-1846-7915
New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Roles: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Supervision, and Validation.
View all articles by this author
J. Christopher Love https://orcid.org/0000-0003-0921-3144
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Roles: Conceptualization, Project administration, Supervision, and Writing - review & editing.
View all articles by this author
Dan H. Barouch https://orcid.org/0000-0001-5127-4659
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Roles: Data curation, Investigation, Project administration, Resources, and Supervision.
View all articles by this author
Francois Villinger https://orcid.org/0000-0002-7790-2008
New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Department of Biology, University of Louisiana at Lafayette, New Iberia, LA 70560 USA.
Roles: Conceptualization, Investigation, Methodology, Project administration, Resources, Supervision, Validation, and Writing - review & editing.
View all articles by this author
Ruth M. Ruprecht
New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Roles: Funding acquisition, Project administration, and Supervision.
View all articles by this author
Darrell J. Irvine* https://orcid.org/0000-0002-8637-1405 djirvine@mit.edu
Funding Information
National Institutes of Health: INV-004954
National Cancer Institute: P30-CA14051
National Institute of Allergy and Infectious Diseases: P01AI048240
National Institute of Allergy and Infectious Diseases: UM1AI144462
National Institute of Allergy and Infectious Diseases: P01AI048240
National Institute of Allergy and Infectious Diseases: P01AI048240
James S. McDonnell Foundation: 10.37717/220020569
U.S. Army Research Office: W911NF-18-2-0048
https://www.science.org/doi/epdf/10.1126/scitranslmed.abn1413
https://www.researchgate.net/publication/362145638_Intranasal_vaccination_with_lipid-conjugated_immunogens_promotes_antigen_transmucosal_uptake_to_drive_mucosal_and_systemic_immunity
Your Next COVID Vaccination Could Be a Nasal Spray: Here's Why
Alyssa Hui - Yesterday 10:41 AM
https://www.msn.com/en-us/health/medical/your-next-covid-vaccination-could-be-a-nasal-spray-here-s-why/ar-AA10eExH?ocid=msedgdhp&pc=U531&cvid=487be11ea72947f6973f724f1f23825f
The invention discloses an influenza Virosome (VI) -coated bionic nano vaccine and a preparation method thereof, the bionic nano vaccine comprises an influenza virosome, small-particle-size fluorinated particles and a DNA vaccine, the bionic nano vaccine is a core-shell structure nano system, VI is a lipid vesicle containing influenza virus envelope protein, the inner core of the nano system is the small-particle-size fluorinated particles loaded with the DNA vaccine, and the influenza virosome is coated on the surface of the inner core. The virosome of the invention has the receptor binding activity, the lysosome membrane fusion activity and the antigen activity of influenza virus; the small particle size of the fluorinated inner core can deliver DNA into the core and promote protein expression. The nano system can realize the joint loading of the protein vaccine and the DNA vaccine and the site-specific delivery of each component, and finally obtains a synergistic effect to improve the immune effect. The invention belongs to the field of pharmaceutical preparations and the technical field of biological medicines, can effectively prevent influenza virus infection, and has high clinical application value.
https://patents.google.com/patent/CN110772635A/en
Study investigates the production of a virosome-based COVID-19 vaccine candidate
Implications
This research shows that an insect cells-baculovirus expression vector system can be used to create high-quality SARS-CoV-2 S protein for the implementation in a virosome-based COVID-19 vaccine candidate. The authors claim that the bioprocessing engineering approach used here permitted them to produce 4 mg/L of full-length S protein, which is the greatest value achieved to date utilizing insect cells.
Furthermore, the S protein produced from insect Sf-9 cells showed glycan processing identical to mammalian cells and mid-term storage durability. Moreover, even after a month of storage at 4 °C, the S protein on the exterior of the virosomes had the capacity to bind to the ACE2 receptor and was recognized by a wide range of neutralizing antibodies. Immunogenicity and safety-toxicology investigations in appropriate animal models should be carried out to verify these particles as COVID-19 vaccine candidates.
https://www.news-medical.net/news/20220418/Study-investigates-the-production-of-a-virosome-based-COVID-19-vaccine-candidate.aspx
A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike.
van der Velden YU1, Grobben M1, Caniels TG1, Burger JA1, Poniman M1, Oomen M1, Rijnstra ES2, Tejjani K1, Guerra D1,
Ronald Kempers
Mymetics BV, JH Oortweg 21, 2333 CH, Leiden, The Netherlands.
Search articles by 'Ronald Kempers'
Kempers R3, Stegmann T3, van Gils MJ1, Sanders RW1
Funding
This work was supported by a Netherlands Organization for Scientific Research (NWO) Vici Grant (to R.W.S.); by the Bill & Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (CAVD) Grants OPP1111923, OPP1132237, and INV-002022 to R.W.S. and INV-024617 to M.J.v.G. M.J.v.G. is a recipient of an AMC Fellowship from Amsterdam UMC. The funders had no role in study design, data collection, data analysis, data interpretation, or data reporting.
https://europepmc.org/article/PMC/PMC8913678
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
https://clinicaltrials.gov/ct2/show/NCT04448756
M5049, a novel potent and selective inhibitor of toll-like receptors 7 and 8 (TLR 7/8) ... Presentation of synthetic peptides on immunopotentiating reconstituted influenza virosomes is a
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159578187
A novel inactivated virus system (InViS) for a fast and inexpensive ...
https://www.nature.com › articles › s41598-022-15471-5
Jul 08, 2022 · Rhodamine B octadecyl ester perchlorate (R18) was purchased from Merck KGaA (The Netherlands) and dissolved in HLPC grade anhydrous ethanol …
A novel inactivated virus system (InViS) for a fast and inexpensive assessment of viral disintegration
Lea A. Furer, Pietro Clement, Gordon Herwig, René M. Rossi, Farien Bhoelan, Mario Amacker, Toon Stegmann, Tina Buerki-Thurnherr & Peter Wick
https://www.nature.com/articles/s41598-022-15471-5
Conclusions
• The EX-CELL® CD Insect Cell Medium has been formulated to optimize the growth, viability and productivity of the
Sf-rhabdovirus-negative (Sf-RVN®) Insect Cell Line. Combined, these two products form the Sf-RVN® Platform and provide
a high performant rhabdovirus-free BEVS alternative to produce recombinant proteins, Virus-Like Particles (VLP) for viral
vaccines, and Adeno-Associated Viruses (AAV) to treat genetic diseases.
• In this study we demonstrated that the EX-CELL® CD Insect Cell Medium out-performs all media tested, including the not
chemically defined media, for the growth of both Sf-RVN® and Sf9 cells.
• For the Sf-RVN® Insect Cell Line, our data shown that the EX-CELL® CD Insect Cell Medium enables the second-best production
after the EX-CELL® 420 Serum-Free Medium while improving lot-to-lot consistency of the medium, which is a common issue
with hydrolysate containing formulations.
• By comparing the productivity of the two Sf9 cells, we demonstrated that the Sf-RVN® cells had a higher SEAP productivity
than the Sf9 cells, especially when cultivated with companion EX-CELL® CD Insect Cell Medium
https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/marketing/global/documents/261/022/poster-ex-cell-cd-insect-cell-medium-ms.pdf
brevets-patents.ic.gc.ca › opic-cipo › cpdPatent 2935620 Summary - Canadian Patents Database
(e.g., DPPC:cholesterolliposomes), virosomes (e.g., immunopotentiating reconstituted influenza virosomes), and microspheres. [0214]Other adjuvants for use according to certain herein disclosed
Patent 2935620 Summary
(12) Patent Application: (11) CA 2935620
(54) English Title: SINGLE VIAL VACCINE FORMULATIONS
(54) French Title: FORMULATIONS DE VACCIN A FLACON UNIQUE
(72) Inventors :
FOX, CHRISTOPHER B. (United States of America)
VEDVICK, THOMAS S. (United States of America)
BARNES V., LUCIEN (United States of America)
KRAMER, RYAN M. (United States of America)
REED, STEVEN G. (United States of America)
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2935620/summary.html
Insect cells as factories for biomanufacturing.
Biotechnology advances (2011-10-11)
Jean-Christophe Drugmand, Yves-Jacques Schneider, Spiros N Agathos
PMID21983546
ABSTRACT
Insect cells (IC) and particularly lepidopteran cells are an attractive alternative to mammalian cells for biomanufacturing. Insect cell culture, coupled with the lytic expression capacity of baculovirus expression vector systems (BEVS), constitutes a powerful platform, IC-BEVS, for the abundant and versatile formation of heterologous gene products, including proteins, vaccines and vectors for gene therapy. Such products can be manufactured on a large scale thanks to the development of efficient and scaleable production processes involving the integration of a cell growth stage and a stage of cell infection with the recombinant baculovirus vector. Insect cells can produce multimeric proteins functionally equivalent to the natural ones and engineered vectors can be used for efficient expression. Insect cells can be cultivated easily in serum- and protein-free media. A growing number of companies are currently developing an interest in producing therapeutics using IC-BEVS, and many products are today in clinical trials and on the market for veterinary and human applications. This review summarizes current knowledge on insect cell metabolism, culture conditions and applications.
https://www.sigmaaldrich.com/US/en/tech-docs/paper/154388
ORIGINAL RESEARCH article
Front. Bioeng. Biotechnol., 20 May 2022 | https://doi.org/10.3389/fbioe.2022.879078
Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate
www.frontiersin.orgBárbara Fernandes1,2, www.frontiersin.orgMarcos Sousa1,2†, www.frontiersin.orgRute Castro1, www.frontiersin.orgAnja Schäfer3,4, www.frontiersin.orgJulia Hauser3,4, www.frontiersin.orgKai Schulze5, www.frontiersin.orgMario Amacker6,7, www.frontiersin.orgMarco Tamborrini3,4, www.frontiersin.orgGerd Pluschke3,4, www.frontiersin.orgPaula M Alves1,2, www.frontiersin.orgSylvain Fleury6 and www.frontiersin.orgAntónio Roldão1,2
https://internal-journal.frontiersin.org/articles/10.3389/fbioe.2022.879078/full
Characteristics of Insect Cell Baculovirus Expression Vector System
2021-12-03
Insect cell baculovirus expression vector system (IC-BEVS) is one of the four major expression systems (insect cell, bacterial, yeast and mammalian cell expression systems).
With various advantages, IC-BEVS is an important source for the development of new drugs, materials and reagents, widely used for the study of recombinant protein expression[1], production of human and veterinary vaccines and for pharmaceutical application. For example, both Cervarix, GlaxoSmithKline's cervical cancer vaccine and Flubolk, Sanofi's tetravalent influenza vaccine adopt IC-BEVS.
The recombinant COVID-19 vaccine (Sf9 cell), jointly developed by WestVac Biopharma Co., Ltd. and the State/National Key Lab of Biotherapy, West China Hospital of Sichuan University, is also based on IC-BEVS, where the genes of SARS-CoV-2 are introduced into insect cells multiplied in the culture solution to prepare the SARS-CoV-2 S protein, inducing the human body to produce antibodies to block the viral infection. In addition, for the new generation vaccine against Delta and Omicron variants, WestVac has precisely designed the subunit vaccine antigen with stable self-assembled trimeric sequence, on the mature IC-BEVS platform. The vaccine has shown excellent immunogenicity and safety.
http://www.westvacpharma.com/detail/33
Insect Cell Proten Expression
Expression Vector System for Insect Cell
Featured Literature
Merck:/Freestyle/BI-Bioscience/Genomic-Analysis/InsectCell-cover.jpgInsect Cell Expression
Download Now!
A rapid, powerful, virus-free method for heterologous protein expression in insect cells
How does use of the InsectDirect® System benefit me?
Allows protein expression in 48 hours, not 2 to 3 weeks
Omits the need for a time-consuming production of recombinant baculovirus
Provides an option for HT screening of multiple targets
Produces up to 80 µg target protein per 1 ml culture
Includes a protocol that can be scaled for larger culture volumes and higher protein yields
https://www.emdmillipore.com/US/en/life-science-research/genomic-analysis/transfection-protein-expression/insect-expression/rnWb.qB.Eo8AAAFAURAENF7H,nav?ReferrerURL=https%3A%2F%2Fsearch.yahoo.com%2F&bd=1
Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate
Bárbara Fernandes,1,2 Rute Castro,1 Farien Bhoelan,3 Denzel Bemelman,3 Ricardo A. Gomes,1 Júlia Costa,2 Patrícia Gomes-Alves,1,2 Toon Stegmann,3 Mario Amacker,4,5 Paula M. Alves,1,2 Sylvain Fleury,4 and António Roldão1,2,*
Wouter L. J. Hinrichs, Academic Editor
Author information Article notes Copyright and License information Disclaimer
1iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal; tp.tebi@sednanrefb (B.F.); tp.tebi@ortsacr (R.C.); tp.tebi@semogar (R.A.G.); tp.tebi@sevlap (P.G.-A.); tp.tebi@seuqram (P.M.A.)
2ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal; tp.lnu.bqti@atsocj
3Mymetics BV, J.H. Oortweg 21, 2333 CH Leiden, The Netherlands; moc.scitemym@naleohb.neiraf (F.B.); moc.scitemym@namlemeb.lezned (D.B.); moc.scitemym@nnamgets.noot (T.S.)
4Mymetics SA, Route de la Corniche 4, 1066 Epalinges, Switzerland; moc.scitemym@rekcama.oiram (M.A.); moc.scitemym@yruelf.niavlys (S.F.)
5Department of Biomedical Research (DBMR), Department of Pulmonary Medicine, Bern University Hospital, University of Bern, 3008 Bern, Switzerland
*Correspondence: tp.tebi@oadlora; Tel.: +351-214-469-418
In this study, we developed a scalable bioprocess using the insect cells-baculovirus expression vector system (IC-BEVS) to produce high-quality S protein, stabilized in its pre-fusion conformation, for inclusion in a virosome-based COVID-19 vaccine candidate.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031128/
Merck & Co. Licenses Protein Sciences’ Insect Cell Vaccine Production Platform
February 23, 2012
The PS platform uses engineered baculoviruses to generate recombinant proteins in the expresSF+ insect cell line. Protein Sciences claims the platform is fast, low cost, results in correctly folded and biologically active proteins, and is scalable to large volumes and high cell densities. The BEVS technology has already been applied to the development of prophylactic and therapeutic vaccines against infectious viruses, biodefense applications, cancer, and diabetes, as well as rAAV-based gene therapy products for lipid and CNS disorders, and biologics for wound/tissue repair, viral infections, and inflammatory diseases.
https://www.genengnews.com/topics/drug-discovery/merck-co-licenses-protein-sciences-insect-cell-vaccine-production-platform/
NICE FIND FRIEND!!
Budget & Planning | NIH: National Institute of Allergy and ...
https://www.niaid.nih.gov/about/budget-planning
Individuals and organizations can contribute to the NIAID gift fund by mailing a donation letter and a check or money order payable to the "National Institute of Allergy and Infectious Diseases”
https://www.niaid.nih.gov/sites/default/files/fy2022cj.pdf
INTERESTING
GP41
Immunogen Design for Induction of HIV distal gp41 broadly neutralizing antibodies
5T P01Act AI138211Project 04Year
ALAM, S. MUNIR Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2022 NIAID
NIAID
$1,469,556
View Similar Projects
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model
5T U19Act AI142636Project 04Year 6243
RUPRECHT, RUTH MARGRIT Principal Investigator(s)/ Project Leader(s)
UNIVERSITY OF LOUISIANA AT LAFAYETTE 2021 NIAID
$507,591
View Similar Projects
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
5T U19Act AI142636Project 04Year
RUPRECHT, RUTH MARGRIT Principal Investigator(s)/ Project Leader(s)
FLEURY, SYLVAIN Principal Investigator(s)/ Project Leader(s)
UNIVERSITY OF LOUISIANA AT LAFAYETTE 2021 NIAID
NIAID
$1,719,534
View Similar Projects
Structures and lipid interactions of curvature-inducing membrane peptides by NMR
5T R01Act GM066976Project 17Year
HONG, MEI Principal Investigator(s)/ Project Leader(s)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2021 NIGMS
NIGMS
$337,339
View Similar Projects
Vaccine development and production
5T U19Act AI142636Project 04Year 6242
FLEURY, SYLVAIN Principal Investigator(s)/ Project Leader(s)
UNIVERSITY OF LOUISIANA AT LAFAYETTE 2021 NIAID
$1,077,795
View Similar Projects
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
5T DP1Act DA043893Project 05Year
KIM, PETER S Principal Investigator(s)/ Project Leader(s)
STANFORD UNIVERSITY 2021 NIDA
NIDA
$785,000
View Similar Projects
Design and validation of VLP/mRNA-based vaccine strategies against SARS-CoV2
1T ZIAAct AI001314Project 02Year
LUSSO, PAOLO Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES 2021 NIAID
NIAID
$121,121
View Similar Projects
Immunogen Design for Induction of HIV distal gp41 broadly neutralizing antibodies
5T P01Act AI138211Project 03Year
ALAM, S. MUNIR Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2021 NIAID
NIAID
$1,552,366
View Similar Projects
Structure/Function of HIV/SIV Envelope Transmembrane Glycoprotein Gp41
1T ZIAAct AR041116Project 26Year
WINGFIELD, PAUL T Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES 2021 NIAMS
NIAMS
$136,545
View Similar Projects
Structural study of the HIV1 gp41 coat protein
1T ZIAAct DK075023Project 13Year
BAX, ADRIAAN Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES 2021 NIDDK
NIDDK
$658,712
View Similar Projects
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model
5T U19Act AI142636Project 03Year 6243
RUPRECHT, RUTH MARGRIT Principal Investigator(s)/ Project Leader(s)
UNIVERSITY OF LOUISIANA AT LAFAYETTE 2020 NIAID
$655,586
View Similar Projects
Structures and lipid interactions of curvature-inducing membrane peptides by NMR
5T R01Act GM066976Project 16Year
HONG, MEI Principal Investigator(s)/ Project Leader(s)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2020 NIGMS
NIGMS
$337,339
View Similar Projects
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
5T U19Act AI142636Project 03Year
RUPRECHT, RUTH MARGRIT Principal Investigator(s)/ Project Leader(s)
FLEURY, SYLVAIN Principal Investigator(s)/ Project Leader(s)
UNIVERSITY OF LOUISIANA AT LAFAYETTE 2020 NIAID
NIAID
$1,855,534
View Similar Projects
Vaccine development and production
5T U19Act AI142636Project 03Year 6242
FLEURY, SYLVAIN Principal Investigator(s)/ Project Leader(s)
UNIVERSITY OF LOUISIANA AT LAFAYETTE 2020 NIAID
$938,754
View Similar Projects
Design and validation of VLP/mRNA-based vaccine strategies against SARS-CoV2
1T ZIAAct AI001314Project 01Year
LUSSO, PAOLO Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES 2020 NIAID
NIAID
$67,461
View Similar Projects
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
5T DP1Act DA043893Project 04Year
KIM, PETER S Principal Investigator(s)/ Project Leader(s)
STANFORD UNIVERSITY 2020 NIDA
NIDA
$785,000
View Similar Projects
Covalent capture of small molecule - gp41 complexes
5T R21Act AI140904Project 02Year
GOCHIN, MIRIAM Principal Investigator(s)/ Project Leader(s)
TOURO UNIVERSITY OF CALIFORNIA 2020 NIAID
NIAID
$178,750
View Similar Projects
Immunogen Design for Induction of HIV distal gp41 broadly neutralizing antibodies
5T P01Act AI138211Project 02Year
ALAM, S. MUNIR Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2020 NIAID
NIAID
$2,138,470
View Similar Projects
Structure/Function of HIV/SIV Envelope Transmembrane Glycoprotein Gp41
1T ZIAAct AR041116Project 25Year
WINGFIELD, PAUL T Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES 2020 NIAMS
NIAMS
$857,575
View Similar Projects
Structural study of the HIV1 gp41 coat protein
1T ZIAAct DK075023Project 12Year
BAX, ADRIAAN Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES 2020 NIDDK
NIDDK
$995,227
View Similar Projects
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection
5T R01Act AI125119Project 05Year
HICAR, MARK DANIEL Principal Investigator(s)/ Project Leader(s)
STATE UNIVERSITY OF NEW YORK AT BUFFALO 2020 NIAID
NIAID
$390,782
View Similar Projects
Deep Topological Sampling of Protein Structures
5T R01Act GM118543Project 04Year
DONALD, BRUCE R. Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2020 NIGMS
NIGMS
$306,511
View Similar Projects
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model
1T U19Act AI142636Project 01Year 6243
RUPRECHT, RUTH MARGRIT Principal Investigator(s)/ Project Leader(s)
TEXAS BIOMEDICAL RESEARCH INSTITUTE 2019 NIAID
$369,510
View Similar Projects
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
1T U19Act AI142636Project 01Year
EDWARDS, DONALD BRUCE Principal Investigator(s)/ Project Leader(s)
FLEURY, SYLVAIN Principal Investigator(s)/ Project Leader(s)
TEXAS BIOMEDICAL RESEARCH INSTITUTE 2019 NIAID
NIAID
$1,213,216
View Similar Projects
Structures and lipid interactions of curvature-inducing membrane peptides by NMR
5T R01Act GM066976Project 15Year
HONG, MEI Principal Investigator(s)/ Project Leader(s)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2019 NIGMS
NIGMS
$337,339
View Similar Projects
Vaccine development and production
1T U19Act AI142636Project 01Year 6242
FLEURY, SYLVAIN Principal Investigator(s)/ Project Leader(s)
TEXAS BIOMEDICAL RESEARCH INSTITUTE 2019 NIAID
$777,557
View Similar Projects
Crystallography and NMR-guided generation of fungal calcineurin inhibitors
5T P01Act AI104533Project 05Year 6760
HEITMAN, JOSEPH Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2019 NIAID
$269,623
View Similar Projects
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
5T DP1Act DA043893Project 03Year
KIM, PETER S Principal Investigator(s)/ Project Leader(s)
STANFORD UNIVERSITY 2019 NIDA
NIDA
$785,000
View Similar Projects
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
7T U19Act AI142636Project 02Year
RUPRECHT, RUTH MARGRIT Principal Investigator(s)/ Project Leader(s)
FLEURY, SYLVAIN Principal Investigator(s)/ Project Leader(s)
UNIVERSITY OF LOUISIANA AT LAFAYETTE 2019 NIAID
NIAID
$727,169
View Similar Projects
Immunogen Design for Induction of HIV distal gp41 broadly neutralizing antibodies
1T P01Act AI138211Project 01A1Year
ALAM, S. MUNIR Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2019 NIAID
NIAID
$1,247,121
View Similar Projects
Covalent capture of small molecule - gp41 complexes
1T R21Act AI140904Project 01A1Year
GOCHIN, MIRIAM Principal Investigator(s)/ Project Leader(s)
TOURO UNIVERSITY OF CALIFORNIA 2019 NIAID
NIAID
$214,500
View Similar Projects
Structural study of the HIV1 gp41 coat protein
1T ZIAAct DK075023Project 11Year
BAX, ADRIAAN Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES 2019 NIDDK
NIDDK
$995,227
View Similar Projects
Structure/Function of HIV/SIV Envelope Transmembrane Glycoprotein Gp41
1T ZIAAct AR041116Project 24Year
WINGFIELD, PAUL T Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES 2019 NIAMS
NIAMS
$499,063
View Similar Projects
Deep Topological Sampling of Protein Structures
5T R01Act GM118543Project 03Year
DONALD, BRUCE R. Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2019 NIGMS
NIGMS
$306,720
View Similar Projects
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection
5T R01Act AI125119Project 04Year
HICAR, MARK DANIEL Principal Investigator(s)/ Project Leader(s)
STATE UNIVERSITY OF NEW YORK AT BUFFALO 2019 NIAID
NIAID
$391,089
View Similar Projects
Deep Topological Sampling of Protein Structures
3T R01Act GM118543Project 03S1Year
DONALD, BRUCE R. Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2019 NIGMS
NIGMS
$170,613
View Similar Projects
Eliciting antibodies to probe native trimeric gp41 for HIV vaccine design
5T R01Act AI114401Project 05Year
ZWICK, MICHAEL B Principal Investigator(s)/ Project Leader(s)
SCRIPPS RESEARCH INSTITUTE, THE 2018 NIAID
NIAID
$574,022
View Similar Projects
Glycan dependent epitopes of HIV broadly neutralizing antibodies
5T R01Act AI113867Project 05Year
PAULSON, JAMES C Principal Investigator(s)/ Project Leader(s)
SCHIEF, WILLIAM R. Principal Investigator(s)/ Project Leader(s)
SCRIPPS RESEARCH INSTITUTE, THE 2018 NIAID
NIAID
$962,498
View Similar Projects
Molecular Characterization of NKp44 Ligand on Astrocytes
5T R03Act NS101481Project 02Year
MATHEW, PORUNELLOOR ABRAHAM Principal Investigator(s)/ Project Leader(s)
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR 2018 NINDS
NINDS
$73,000
View Similar Projects
Development of anti-gp41 HIV-1 antibodies for penetration of blood brain barrier
5T R21Act NS098956Project 02Year
GORNY, MIROSLAW K Principal Investigator(s)/ Project Leader(s)
NEW YORK UNIVERSITY SCHOOL OF MEDICINE 2018 NINDS
NINDS
$188,187
View Similar Projects
Structures and lipid interactions of curvature-inducing membrane peptides by NMR
2T R01Act GM066976Project 14A1Year
HONG, MEI Principal Investigator(s)/ Project Leader(s)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2018 NIGMS
NIGMS
$337,339
View Similar Projects
Crystallography and NMR-guided generation of fungal calcineurin inhibitors
5T P01Act AI104533Project 04Year 6760
HEITMAN, JOSEPH Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2018 NIAID
$298,465
View Similar Projects
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
5T DP1Act DA043893Project 02Year
KIM, PETER S Principal Investigator(s)/ Project Leader(s)
STANFORD UNIVERSITY 2018 NIDA
NIDA
$785,000
View Similar Projects
Structural study of the HIV1 gp41 coat protein
1T ZIAAct DK075023Project 10Year
BAX, ADRIAAN Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES 2018 NIDDK
NIDDK
$995,227
View Similar Projects
Structure/Function of HIV/SIV Envelope Transmembrane Glycoprotein Gp41
1T ZIAAct AR041116Project 23Year
WINGFIELD, PAUL T Principal Investigator(s)/ Project Leader(s)
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES 2018 NIAMS
NIAMS
$554,290
View Similar Projects
Deep Topological Sampling of Protein Structures
5T R01Act GM118543Project 02Year
DONALD, BRUCE R. Principal Investigator(s)/ Project Leader(s)
DUKE UNIVERSITY 2018 NIGMS
NIGMS
$306,928
View Similar Projects
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection
5T R01Act AI125119Project 03Year
HICAR, MARK DANIEL Principal Investigator(s)/ Project Leader(s)
STATE UNIVERSITY OF NEW YORK AT BUFFALO 2018 NIAID
NIAID
$391,389
View Similar Projects
A His-tag Binding Membrane System for Generating Neutralizing Gp41 MPER antibodies
5T R21Act AI122964Project 02Year
LOVELL, JONATHAN F Principal Investigator(s)/ Project Leader(s)
STATE UNIVERSITY OF NEW YORK AT BUFFALO 2017 NIAID
NIAID
$238,115
View Similar Projects
Eliciting antibodies to probe native trimeric gp41 for HIV vaccine design
5T R01Act AI114401Project 04Year
ZWICK, MICHAEL B Principal Investigator(s)/ Project Leader(s)
SCRIPPS RESEARCH INSTITUTE, THE 2017 NIAID
NIAID
$574,022
View Similar Projects
Glycan dependent epitopes of HIV broadly neutralizing antibodies
5T R01Act AI113867Project 04Year
PAULSON, JAMES C Principal Investigator(s)/ Project Leader(s)
SCHIEF, WILLIAM R. Principal Investigator(s)/ Project Leader(s)
SCRIPPS RESEARCH INSTITUTE, THE 2017 NIAID
NIAID
$962,498
View Similar Projects
https://reporter.nih.gov/search/cPyQvwQjdkGuV5EFS2vNmw/projects
Toon Stegmann
SPECIFIC INTERESTS
In the titles of their published articles, experts often reveal their very specific interests.
Here is the title of the one article written by Toon Stegmann in 2012-2022 about Communicable Diseases:
New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes. 2020
Mymetics SA, 4 Route de la Corniche, 1066 Epalinges, Switzerland. · Catalent U.K. Swindon Zydis Limited, Frankland Road, Blagrove, Swindon, SN5 8RU Wiltshire UK. · Upperton Limited, Albert Einstein Centre, Nottingham Science Park, Nottingham, NG7 2TN UK. · Chimera Biotec GmbH, Emil-Figge-Strasse 76A, 44227 Dortmund, Germany. · Mymetics BV, JH Oortweg 21, 2333 CH Leiden, The Netherlands. · 6Bachem AG, Hauptstrasse 144, 4416 Bubendorf, Switzerland. · 7Centre d'immunologie et des Maladies Infectieuses, Sorbonne Université, INSERM U1135, Paris, France. · Pubmed 32435515
https://expertscape.com/au/infectious+diseases/Stegmann%2C+Toon
Jasper BOS
Director
Jasper is a former Merck executive who joined Forbion as General Partner for its Growth Opportunities Fund. Before Forbion, Jasper was Senior Vice President and Managing Director at M Ventures (venture arm of Merck) which he joined in 2009. There he led a team of 21 investment professionals and with a fund size of €400 million invested in over 50 portfolio companies spanning biotech, life sciences tools, and tech companies across the investment spectrum. His track record includes the successful exits of Prexton Therapeutics, Epitherapeutics, Galecto, ObsEva, Translate Bio, and F-Star. Jasper holds a PhD in Pharmacy from the University of Groningen, the Netherlands.
Anaveon AG
Technologiepark Basel
Hochbergerstrasse 60C
4057 Basel
Switzerland
https://anaveon.com/board/
Hey! Corpus when's the BIG BONANZA? Let me Know!!!!!
European nanomedicine projects | ETPN
https://etp-nanomedicine.eu/about-nanomedicine/...
ETP-Nanomedicine Type: Coordination & support actions (CSA) H2020 ID: 766492 Starting: 2017-10-01 Finishing: 2020-09-30 ... Mymetics BV Type: Research & Innovation actions (RIA) H2020 ID:
Nanomedicine:
Maciviva
Summary / Tagline:
Manufacturing process for Cold-chain Independent VIrosome-based VAccines
Coordinator:
Mymetics BV
Type:
Research & Innovation actions (RIA)
H2020 ID:
646122
Starting:
2015-05-04
Finishing:
2018-11-03
Links:
Website | E-Mail | Cordis
https://etp-nanomedicine.eu/about-nanomedicine/european-nanomedicine-projects/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163371612
People also ask
Can virosome make tumor-specific tumor antigens?
Virosome could make delivery tumor antigens, including Tumor-Specific Antigens (TSA) and Tumor-Associated Antigens (TAA). Virosome compression to the viral vector has much safety and is persuaded to be used.
Virosome-based nanovaccines; a promising bioinspiration and biomim…
www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Search for: Can virosome make tumor-specific tumor antigens?
What are the advantages of virosome delivery system?
The significant advantage of the virosomes delivery system is adsorbing epitopes of antigens via hydrophobic domains or lipid linker on their surface and inside, furthermore, integrating into phospholipid bilayer.
Virosome-based nanovaccines; a promising bioinspiration and biomim…
www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Search for: What are the advantages of virosome delivery system?
What triggers antibody-dependent cellular phagocytosis in HIV-1 infection?
Duchemin M., Tudor D., Cottignies-Calamarte A., Bomsel M. Antibody-dependent cellular phagocytosis of HIV-1-infected cells is efficiently triggered by IgA targeting HIV-1 envelope subunit gp41. Front. Immunol. 2020;11[PMC free article][PubMed] [Google Scholar]
Virosome-based nanovaccines; a promising bioinspiration and biomim…
www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Search for: What triggers antibody-dependent cellular phagocytosis in HIV-1 infection?
What is the efficacy of fusogenic virosome?
The efficacy of fusogenic virosome dramatically depends on the detergents used. After solubilization, it is also challenging to remove low-CMC detergents like octaethylene glycol mono (n-dodecyl) ether (C12E8), Triton X-100, nonidert p-40, and others.
Virosome-based nanovaccines; a promising bioinspiration and biomim…
www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Search for: What is the efficacy of fusogenic virosome?
Interesting:
Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases
Published online 2022 Mar 3
Numerous pathogenic microbes, including viruses, bacteria, and fungi, usually infect the host through the mucosal surfaces of the respiratory tract, gastrointestinal tract, and reproductive tract. The mucosa is well known to provide the first line of host defense against pathogen entry by physical, chemical, biological, and immunological barriers, and therefore, mucosa-targeting vaccination is emerging as a promising strategy for conferring superior protection. However, there are still many challenges to be solved to develop an effective mucosal vaccine, such as poor adhesion to the mucosal surface, insufficient uptake to break through the mucus, and the difficulty in avoiding strong degradation through the gastrointestinal tract. Recently, increasing efforts to overcome these issues have been made, and we herein summarize the latest findings on these strategies to develop mucosa-targeting vaccines, including a novel needle-free mucosa-targeting route, the development of mucosa-targeting vectors, the administration of mucosal adjuvants, encapsulating vaccines into nanoparticle formulations, and antigen design to conjugate with mucosa-targeting ligands. Our work will highlight the importance of further developing mucosal vaccine technology to combat the frequent outbreaks of infectious diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952777/
This is Interesting:
Most melanomas are present in the skin. However, mucosal melanomas occur in the mucous membranes, such as the eyes, mouth, gastrointestinal tract, anus, or vagina.
https://www.medicalnewstoday.com/articles/mucosal-melanoma
so this made the National Library of Medicine:
PATENT SUMMARY
Virosome-like vesicles comprising gp41-derived antigens
Patent WO-2007099446-A3
Inventor
FLEURY SYLVAIN (CH)
BOMSEL MORGAN (FR)
ZURBRIGGEN RINALDO (CH)
Assignee
MYMETICS CORP (US)
INST NAT SANTE RECH MED (FR)
PEVION BIOTECH LTD (CH)
FLEURY SYLVAIN (CH)
BOMSEL MORGAN (FR)
https://pubchem.ncbi.nlm.nih.gov/patent/WO-2007099446-A3
rulessbreinstatingdaca119.blogspot.com Biden administration proposes
A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike Scientific Reports ABC, Israel nearing quota of 5K non Jewish Ukrainian
https://rulessbreinstatingdaca119.blogspot.com/
Rogier W. Sanders
https://www.amsterdamumc.org/en/research/researchers/rogier-w.-sanders.htm
We review how this technique emerged during HIV-1 Env vaccine development and its subsequent wider application to other viral vaccines including SARS-CoV-2.
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(21)00048-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1931312821000482%3Fshowall%3Dtrue